Startup · $108m raised
Melbourne, VIC
Every investor coverage indicates participated in a round Aravax raised.
| Investor | Rounds | Invested |
|---|---|---|
| Agati Capital | Series B | - |
| Brandon Capital | Series B · Series B | - |
| Breakthrough Victoria | undisclosed · Series B | $12,000,000 |
| Novartis Venture Fund | Series B | - |
| Tenmile | Series B · Series B | - |
| Uniseed | Series B | - |
| UniSuper | Series B | - |
Investors whose own portfolio pages list Aravax, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
Companies Aravax acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Aravax. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The US medicines regulator has granted Fast Track designation to Aravax's peanut-allergy immunotherapy PVX108, easing its development path; the Melbourne-based biotech expects Phase 2 data later in 2026.
Breakthrough Victoria rounds up April–May 2026 portfolio news, including grants for Number 8 Bio and Xefco, Liquid Instruments' Series C, program selections, partnerships, regulatory clearances and two new Aravax directors.
Melbourne biotech Aravax, developer of the peanut allergy immunotherapy PVX108, adds former ALK-Abello chief Carsten Hellmann and ex-Aimmune commercial head Andrew Oxtoby to its board ahead of Phase 3.
Uniseed's site announces that Aravax has appointed Carsten Hellmann and Andrew Oxtoby to its board.
Profile tracing Sara Prickett's path from UK labs to co-founding Aravax, the peanut-allergy biotech Brandon Capital backed, as its Phase II trial nears readout in mid-2026.
Breakthrough Victoria's CEO reviews its 2024/25 year: growing capital base, strong co-investment leverage, portfolio milestones including Amber's $10m raise, first fellows awarded, and projected economic impact ahead.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·SmartCompany·SmartCompany·RenewEconomy
A profile of Brandon Capital partner Chris Smith, tracing his path from immunology research and a Cambridge postdoc into biotech investing, with resilience lessons drawn from equestrian sport and companies Aravax and ENA Respiratory.
Breakthrough Victoria highlights recent achievements of portfolio companies including funding, awards, and expansions for firms like Liquid Instruments, Quantum Brilliance, and Samsara Eco.
Aravax has finished enrolling 95 young patients in its Phase 2 peanut-allergy immunotherapy trial across US and Australian sites, with results expected in the first half of 2026.
Breakthrough Victoria's yearly investment review reports sixteen new portfolio companies backed in FY23/24, itemising five with amounts — Xefco, Raygen, Jupiter Ionics, Bygen, Aravax — and cumulative investment beyond $300 million.
Also SmartCompany
Breakthrough Victoria defends its spending and investment record against critics urging its abolition, pointing to portfolio companies, university partnerships and recent backing of startups including Aravax.
Breakthrough Victoria's media release marks three years, citing more than $300 million committed across direct investments, a fund, a grant and university partnerships, and discusses its Aravax and Seer Medical investments.
Breakthrough Victoria announces a $12 million investment in Aravax, part of a $66 million Series B, advancing the biotech's peanut allergy immunotherapy into phase two trials in Australia and the United States.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·Business News Australia·@AuManufacturing·Forbes Australia·Startup News (WA)
Techboard's monthly roundup catalogues December 2022 startup raises, led by Synchron's $110m Series C, with health and biotech taking the largest share and 55 funding events captured totalling $546m.
Biotech Aravax has received a US$20 million Series B commitment from Brandon Capital and Tenmile to advance its peanut allergy therapy PVX108 into Phase 2 trials.
Also Brandon Capital portfolio·Startup Daily·Startup News (WA)·Techboard·Startup Daily
Aravax has begun its Series B with a US$20 million investment from Brandon Capital and Tenmile, funding Phase 2 trials of its peanut allergy immunotherapy PVX108 while it seeks further capital.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Forbes Australia·Techboard·Business News Australia
Clinical-stage biotech Aravax has added pharma veteran Dr Brett Haumann, formerly of ReViral, Theravance, GSK and Aimmune, as a non-executive director ahead of a Phase 2 study of its peanut allergy therapy PVX108.
Aravax clears its US FDA application to trial its peanut-allergy immunotherapy PVX108 in Phase 2 studies across two countries, and adds a prominent food-allergy paediatric specialist to its scientific advisory board.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia
Biotech firm Aravax has added Thomas Ulmer, previously CFO at Immatics and Allergopharma with Merck roles, to its board as its peanut allergy treatment advances after positive phase 1 safety results.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily